Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Amgen Paying $1.9bn For Five Prime And Its Gastric Cancer Antibody

Cancer — Amgen thinks Five Prime's bemarituzumab offers utility in various tumor types

Related Content

Deal Watch: Pfizer Begins 2018 With Two Deals, Including ALS Tie-Up With Sangamo

Jan 04 2018

Amgen Eschews Some Of Its BiTEs, But Otezla Spurs Growth

Feb 03 2021

While Amgen Sees Success For Two Growth Drivers, Headwinds Remain

Feb 02 2021

Five Prime Lands Blow On Gastric Cancers With FGFR2b Antibody

Nov 11 2020

Related Companies

Amgen, Inc.

Five Prime Therapeutics, Inc.

Zai Lab Ltd.

BeOne Medicines Ltd.

Additional Topics

M & A Deals Business Strategies Commercial Cancer BioPharmaceutical

More from Deals

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window